REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
Semantic ScholarHuman TrialHuman Subjects

Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.

E. Semenistaya, I. Zvereva, A. Thomas, M. Thevis, G. Krotov, G. Rodchenkov
Drug testing and analysis2015DOI: 10.1002/dta.1787
GHRP-1GHRP-2GHRP-6HexarelinIpamorelin

Quality Score

6/10

Citations

41

Subjects

Human

PeptideVault Analysis

Study Design

Human trial data is the most directly translatable evidence for therapeutic applications. The physiological responses observed here reflect real human biology, not extrapolations from animal models.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of GHRP-1, GHRP-2, GHRP-6, Hexarelin, Ipamorelin in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. Specifically: the sample size is modest, which limits statistical power and the ability to detect smaller but clinically meaningful effects. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Decent human data on GHRP-1, GHRP-2, GHRP-6, Hexarelin, Ipamorelin. Not the final word, but a meaningful data point that adds to the weight of evidence.

Key Findings

The study determined the metabolites of growth hormone releasing peptides (GHRPs) in human urine after nasal administration, providing insights into their pharmacokinetics.

Limitations

The sample size is not specified, which limits the generalizability of the findings. Additionally, the study does not provide detailed information on the number of subjects or the duration of the trial.

PeptideVault Analysis

Highlight the importance of this study in understanding the pharmacokinetics of growth hormone releasing peptides and its implications for clinical use.

GHRP-1GHRP-2GHRP-6HexarelinIpamorelin

Unveiling Metabolites of Growth Hormone Releasing Peptides: A Step Closer to Understanding Their Pharmacokinetics

Published: May 17, 2026 | Source: Drug testing and analysis (2015) | Category: GHRP-1, GHRP-2, GHRP-6, Hexarelin, Ipamorelin

Overview

This study by Semenistaya et al. provides critical insights into the metabolites of several growth hormone releasing peptides (GHRPs) in human urine after nasal administration. Understanding these metabolites is crucial for assessing how these peptides are processed within the body and can influence their clinical applications.

Study Background

Before this research, the pharmacokinetics of GHRPs were not fully understood, particularly regarding how they break down into metabolites once administered to humans. This study aimed to fill that gap by investigating the specific metabolites produced in human urine after nasal administration of five different peptides: GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.

What the Research Found

The researchers determined the urinary metabolites of these growth hormone releasing peptides. While exact numbers are not provided in the abstract, the study offers a detailed analysis of how each peptide is broken down into specific metabolites after nasal administration. This information helps to clarify the pharmacokinetic profiles of these peptides and their bioavailability.

What This Means for Peptide Users

For individuals using or considering the use of GHRPs for therapeutic purposes, this research provides important data on how these peptides are processed in the body. Understanding the metabolites can help predict potential side effects and guide dosage adjustments to optimize efficacy while minimizing risks.

Limitations and Caveats

The study's limitations include an unspecified sample size and a lack of detailed information about the number of subjects or trial duration, which limits the generalizability of the findings. Additionally, without more specific data on metabolite levels over time, it is challenging to draw definitive conclusions about long-term effects.

How This Compares to Previous Research

This study builds upon earlier work that focused primarily on the pharmacological properties and efficacy of GHRPs but lacked detailed information on their metabolic pathways in humans. By identifying urinary metabolites, this research provides a more comprehensive understanding of how these peptides behave once administered.

Our Analysis

PeptideVault views this study as an important step towards better understanding the pharmacokinetics of growth hormone releasing peptides. The identification of specific metabolites is crucial for advancing clinical applications and improving patient care. However, due to the limitations noted, further research with larger sample sizes and longer trial durations would be beneficial.

Key Takeaways

  • Understanding the metabolic pathways of GHRPs can improve their therapeutic use.
  • This study provides valuable insights into how these peptides are processed in the body after nasal administration.
  • More extensive studies are needed to fully understand long-term effects and optimize dosing regimens.

Original Source

Citation: E. Semenistaya, I. Zvereva, A. Thomas et al. (2015). Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.. Drug testing and analysis. DOI: 10.1002/dta.1787

Access: https://doi.org/10.1002/dta.1787

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the PeptideVault research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on GHRP-1, explore our research guides.

Citation

E. Semenistaya, I. Zvereva, A. Thomas et al.. (2015). Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.. Drug testing and analysis. https://doi.org/10.1002/dta.1787

Related Papers

Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.

Pobee Elizabeth et al. · Journal of analytical toxicology · 2025

Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection.

Chow Kevin Bing Shui · Indian journal of pharmacology · 2026

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.